Working without patients: a new strategy to improve the glycemic control in patients with type 2 diabetes. Avoiding therapeutic inertia
e202110133
Keywords:
Diabetes mellitus, Glycemic control, Prevention and control, Disease managementAbstract
Working without patients: a new strategy to improve the glycemic control in patients with type 2 diabetes. Avoiding therapeutic inertia.
Background: Inertia has been described as one of the causes of persistent poor glycemic control. The aim of this study was to evaluate, after one year of implementation in a health area, the effect of an intervention to improve the degree of glycemic control of patients with type 2 diabetes (DM2).
Methods: A pre-post intervention study was carried out in one health department during 2018. Health department with 222,767 inhabitants, 111 primary care physicians and 14,154 patients with DM2. Each primary care physician reviewed, outside consultation hours (“working without patients”), the electronic health record to identify patients with DM2 and with poor glycemic control, and they cited them for review. The glycemic control for the month of December 2017 and 2018 were compared, defined as the percentage of patients who reach the control objective of glycosylate hemoglobin (HbA1c).
Results: The proportion of patients with good glycemic control was 44.8% in 2017 and 50.1% in 2018, being the department that obtained the greatest improvement in the indicator in 2018 in the Valencian Community. The proportion of primary care physicians that had at least half of their patients with good glycemic control increased from 39% to 51% after the intervention.
Conclusions: The strategy “working without patients” was associated with an improvement in the degree of glycemic control of patients with DM2.
Downloads
References
Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic
review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172:761–769.
Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.
Ye N, Yang L, Wang G, Bian W, Xu F, Ma C et al. Admission fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project. BMC Cardiovasc Disord. 2020 Aug 20;20(1):380.
Mitsios JP, Ekinci EI, Mitsios GP, Churilov L, Thijs V. Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2018 May 17;7(11):e007858.
Cavero-Redondo I, Peleteiro B, Álvarez-Bueno C, Rodriguez-Artalejo F, Martínez-Vizcaíno V. Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis. BMJ Open. 2017 Jul 31;7(7):e015949.
Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014 Jun 7;383(9933):2008-2017.
Hua X, Lung TW, Palmer A, Si L, Herman WH, Clarke P. How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. Pharmacoeconomics. 2017 Mar;35(3):319-329.
Orozco-Beltrán D, Navarro-Pérez J, Cebrián-Cuenca AM, Álvarez-Guisasola F, Caride-Miana E, Mora G et al. The influence of hemoglobin A1c levels on cardiovascular events and all-cause mortality in people with diabetes over 70 years of age. A prospective study. Prim Care Diabetes. 2020 Jun 27:S1751-9918(20)30215-1.
Mata-Cases M, Franch-Nadal J, Real J, Mauricio D. Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study. BMJ Open2016;6:e012463.
Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694.
Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL et al. Clinical inertia. Ann Intern Med. 2001; 135:825–834.
Mata-Cases M. Inercia terapéutica en el tratamiento de la diabetes tipo 2. Diabetes Práctica 2017;08(Supl Extr 1):1-20.
Jude EB, Nixon M, O’Leary C, Myland M, Gooch N, Shaunik A et al. Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study. Diabetes Ther. 2019 Oct;10(5):1847-1858.
Gil-Guillen V, Orozco-Beltran D, Redon J, Pita-Fernandez S, Navarro-Pérez J, Pallares V et al. Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia. BMC Public Health. 2010 Nov 22;10:717.
Mateo-Gavira I, Carrasco-García S, Larran L, Fierro MJ, Zarallo A, Mayoral Sánchez E et al; en nombre del Grupo de Trabajo IEMAC-CAD, Cádiz; Grupo de Trabajo IEMAC-Cádiz. Specific model for the coordination of primary and hospital care for patients with diabetes mellitus. Evaluation of two-year results (2015-2017). Endocrinol Diabetes Nutr. 2020 Jun 3:S2530-0164(20)30070-7.
Vélez JM, García R, Pina E, Morales C, Escalera C, Ortega A et al. Eficacia de una estrategia para mejorar los indicadores de calidad del Proceso Asistencial Integrado Diabetes Mellitus 2 en el Centro Avanzado de Diabetes Macarena [Efficacy of the strategy to improve the quality indicators of Diabetes Mellitus 2 Care Process in Advanced Diabetes Centre Macarena]. Aten Primaria. 2019 Jan;51(1):18-23.
Guía del Plan de Salud 2016-2020 de la Comunidad Valenciana. Disponible en: http://www.san.gva.es/documents/157385/6431837/Guia_CAST_web.pdf (Último acceso 30 de diciembre de 2020)
Estrategia de Diabetes de la Comunidad Valenciana 2017-2021. Disponible en: http://publicaciones.san.gva.es/publicaciones/documentos/EDCV_2017-2021-C.pdf. (Ultimo acceso 23 de septiembre de 2020).
Gabbay RA, Kendall D, Beebe C, Cuddeback J, Hobbs T, Khan ND et al. Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. Clin Diabetes. 2020 Oct;38(4):371-381.
Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. 2010 Dec;4(4):203-207.
Mata-Cases M, Franch-Nadal J, Real J, Gratacòs M, López-Simarro F, Khunti K et al. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: factors predicting intensification of treatment. Diabetes Obes Metab 2018;20:103–112.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80.000 people. Diabetes Care 2013;36:3411-3417.
American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44 (Suppl 1):S73-S84.
de Pablos-Velasco P, Parhofer KG, Bradley C, Eschwège E, Gönder-Frederick L, Maheux P et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014 Jan;80(1):47-56.
Stone MA, Charpentier G, Doggen K, Kuss O, Lindblad U, Kellner C et al; GUIDANCE Study Group. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care. 2013 Sep;36(9):2628-2638.
Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015 Mar;175(3):356-362.
Alvarez-Guisasola F, Cebrián-Cuenca AM, Cos X, Ruiz-Quintero M, Millaruelo JM, Cahn A et al; Spanish Society of Family Medicine Diabetes Group. Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real-life clinical practice. Diabetes Metab Res Rev. 2018 Mar;34(3).
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Domingo Orozco-Beltrán, Francisco Pomares-Gómez , Paz Ortega-Ruiz, Juan Molina Ribera, Norma Iranzo-García, Unidad funcional de diabetes del Centro Avanzado de Diabetes (Departamento de Salud Alicante-Sant Joan d’Alacant)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
